Asuragen this month published details about its development of miRInform Pancreas, a microRNA-based test for differentiating pancreatitis from pancreatic ductal adenocarcinoma, and stressed the importance of the validation process during the development of these kinds of tests.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.